Lab study hopes to unlock ARDS treatment using patient blood cells
NCT ID NCT07125079
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at blood from people with ARDS, a severe lung condition with no specific medicines. Researchers will take immune cells from the blood and test a new blocking agent in the lab to see if it can reduce lung damage. The goal is to learn more about the disease and find possible treatments. No new drugs are given to patients in this study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cell infusion aims to free ARDS patients from ventilators
- New ventilation strategy aims to reduce lung damage in severe pneumonia
- Scientists build a biobank to decode ARDS and personalize treatment
- Scientists hunt for hidden ARDS subtypes to crack deadly lung failure
- Simple chest squeeze may replace High-Tech ventilator settings
- New study uses imaging to see how nitric oxide helps ARDS lungs